In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6. Dr. Marwan G. Fakih discussed the FDA approval of ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF V600E mutation. The regimen demonstrated a 60.9% confirmed ORR ...

Braftovi (encorafenib), for treating patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. Braftovi is an oral small-molecule kinase inhibitor that targets BRAF V600E.

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has ... the combination in mCRC patients living with a BRAF V600E mutation who are treatment-naive. The top-line data also ...

such as melanoma or colorectal. There are several types of BRAF mutation that can occur, but the most common type is V600E. Adenocarcinoma refers to the location where lung cancer starts.

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal cancer.

in combination with cetuximab and mFOLFOX6 has yielded positive results for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. According to InvestingPro, Pfizer ...